Cerecor

Cerecor is a biopharmaceutical company dedicated to becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies to address unmet patient needs in rare and orphan diseases. Its rare disease pipeline includes CERC-801, CERC-802, and CERC-803 (being developed for the treatment of congenital disorders of glycosylation) and CERC-006 (an oral mTORc1/c2 inhibitor being developed for the treatment of complex lymphatic malformations). The company is also developing two monoclonal antibodies, CERC-002 and CERC-007.